JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ISRG

478.08

-0.13%↓

ABT

108.15

-0.74%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ISRG

478.08

-0.13%↓

ABT

108.15

-0.74%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ISRG

478.08

-0.13%↓

ABT

108.15

-0.74%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ISRG

478.08

-0.13%↓

ABT

108.15

-0.74%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ISRG

478.08

-0.13%↓

ABT

108.15

-0.74%↓

MannKind Corp

Затворен

СекторЗдравеопазване

5.78 -6.92

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

5.75

Максимум

6.26

Ключови измерители

By Trading Economics

Приходи

7.3M

8M

Продажби

5.6M

82M

P/E

Средно за сектора

50.7

84.243

Марж на печалбата

9.722

Служители

403

EBITDA

8.1M

18M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+54.74% upside

Дивиденти

By Dow Jones

Следващи печалби

25.02.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-125M

1.6B

Предишно отваряне

12.7

Предишно затваряне

5.78

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

MannKind Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.02.2026 г., 22:55 ч. UTC

Печалби

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4.02.2026 г., 21:44 ч. UTC

Печалби

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4.02.2026 г., 21:39 ч. UTC

Печалби

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

4.02.2026 г., 23:46 ч. UTC

Печалби

Arm Holdings Expects Slower Revenue Growth in 4Q -- Update

4.02.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4.02.2026 г., 23:45 ч. UTC

Горещи акции

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4.02.2026 г., 23:45 ч. UTC

Печалби

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4.02.2026 г., 23:32 ч. UTC

Пазарно говорене

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4.02.2026 г., 22:59 ч. UTC

Придобивния, сливания и поглъщания

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4.02.2026 г., 22:30 ч. UTC

Печалби

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4.02.2026 г., 22:30 ч. UTC

Печалби

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4.02.2026 г., 22:21 ч. UTC

Печалби

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4.02.2026 г., 22:17 ч. UTC

Пазарно говорене

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4.02.2026 г., 22:15 ч. UTC

Пазарно говорене

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4.02.2026 г., 22:00 ч. UTC

Пазарно говорене

ESG Roundup: Market Talk

4.02.2026 г., 21:53 ч. UTC

Печалби

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4.02.2026 г., 21:51 ч. UTC

Печалби

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене
Печалби

Auto & Transport Roundup: Market Talk

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

4.02.2026 г., 21:45 ч. UTC

Печалби

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4.02.2026 г., 21:44 ч. UTC

Печалби

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4.02.2026 г., 21:43 ч. UTC

Печалби

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4.02.2026 г., 21:41 ч. UTC

Печалби

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4.02.2026 г., 21:36 ч. UTC

Пазарно говорене

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4.02.2026 г., 21:30 ч. UTC

Печалби

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4.02.2026 г., 21:30 ч. UTC

Печалби

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4.02.2026 г., 21:30 ч. UTC

Печалби

Beach Energy Interim Dividend 1 Australian Cent/Sjare

4.02.2026 г., 21:30 ч. UTC

Печалби

Steris Sees FY Adj EPS $10.15-Adj EPS $10.30 >STE

Сравнение с други в отрасъла

Ценова промяна

MannKind Corp Прогноза

Ценова цел

By TipRanks

54.74% нагоре

12-месечна прогноза

Среден 9.3 USD  54.74%

Висок 11 USD

Нисък 7.5 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за MannKind Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

6

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

4.079 / 4.323Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
help-icon Live chat